General Information of Drug (ID: DMXGDFK)

Drug Name
FENBUFEN Drug Info
Synonyms
fenbufen; 36330-85-5; Lederfen; Cinopal; Napanol; Bufemid; 4-(4-Biphenylyl)-4-oxobutyric acid; 3-(4-Phenylbenzoyl)propionic acid; 3-(4-Biphenylylcarbonyl)propionic acid; 4-(biphenyl-4-yl)-4-oxobutanoic acid; gamma-Oxo(1,1'-biphenyl)-4-butanoic acid; 3-(4-Biphenylcarbonyl)propionic acid; Cinopol; Fenbufenum [INN-Latin]; Fenbufene [INN-French]; 4-([1,1'-biphenyl]-4-yl)-4-oxobutanoic acid; CL-82204; CL 82204; 4-biphenyl-4-yl-4-oxobutanoic acid; Butyric acid 4-(4-biphenyl)-4-oxo-; UNII-9815R1WR9B; 4-oxo-4-(4-phenylphenyl)butanoic a
Indication
Disease Entry ICD 11 Status REF
Arthritis FA20 Approved [1]
Cross-matching ID
PubChem CID
3335
ChEBI ID
CHEBI:31599
CAS Number
CAS 36330-85-5
TTD Drug ID
DMXGDFK
VARIDT Drug ID
DR01176

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Prostaglandin G/H synthase 1 (COX-1) TT8NGED PGH1_HUMAN Inhibitor [2]
Prostaglandin G/H synthase 2 (COX-2) TTVKILB PGH2_HUMAN Inhibitor [2]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Prostaglandin G/H synthase 1 (COX-1) DTT PTGS1 6.09 7.747 6.04 7.023
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Arthritis
ICD Disease Classification FA20
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Prostaglandin G/H synthase 2 (COX-2) DTT PTGS2 7.93E-04 -0.29 -0.34
Prostaglandin G/H synthase 1 (COX-1) DTT PTGS1 3.97E-03 0.16 0.43
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
2 Fenbufen based 3-[5-(substituted aryl)-1,3,4-oxadiazol-2-yl]-1-(biphenyl-4-yl)propan-1-ones as safer antiinflammatory and analgesic agents. Eur J Med Chem. 2009 Sep;44(9):3798-804.